title: Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase.
authors.forename: A
authors.initials: A
authors.lastname: Vora
authors.forename: M
authors.initials: M
authors.lastname: Bhutani
authors.forename: A
authors.initials: A
authors.lastname: Sharma
authors.forename: V
authors.initials: V
authors.lastname: Raina
mesh_terms: D000293:Adolescent; D001549:Benzamides; D001707:Biopsy, Needle; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment; D012720:Severity of Illness Index; D015275:Tumor Lysis Syndrome / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate